Nuvation Bio Inc. NUVB
- Market cap
- $2.0B
- P/E
- 0.0×
Follow NUVB
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 9.55 | 7.30 | 1.59 | 0.95 | 1.43 | 1.54 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 12.52 | 15.23 | 8.88 | 2.55 | 4.16 | 9.75 |
High Price
|
|||
| — | — | — | 5 | 36 | 64 | 53 | 51 | 220 | 298 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | 8 | 63 |
Revenue
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | — | 10.10% | 85.22% |
Gross Margin
|
|||
| — | — | — | — | (42) | (87) | (104) | (76) | (568) | (205) |
EBT
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | (7,213.76%) | (325.31%) |
EBT Margin
|
|||
| — | 0 | — | 0 | (42) | (87) | (104) | (76) | (568) | (205) |
Net Income
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 1 | 2 |
Depreciation
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.18 |
Revenue/Sh
|
|||
| — | — | — | — | (0.43) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
Earnings/Sh
|
|||
| — | — | — | — | (0.37) | (0.34) | (0.44) | (0.31) | (0.49) | (0.51) |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) |
Capex/Sh
|
|||
| — | — | — | — | (0.38) | (0.35) | (0.45) | (0.31) | (0.49) | (0.53) |
Free CF/Sh
|
|||
| — | — | — | — | 2.21 | 3.77 | 3.02 | 2.76 | 1.73 | 0.90 |
Book Value/Sh
|
|||
| — | — | — | — | 98 | 198 | 217 | 219 | 269 | 342 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 48.65 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 1.54 | 10.01 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 41.08 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (1.69) | (14.87) |
EV/FCF
|
|||
| — | — | — | — | (37) | (68) | (96) | (68) | (130) | (173) |
Op' Cash Flow
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | (8) |
Capex
|
|||
| — | — | — | — | (37) | (68) | (96) | (68) | (131) | (182) |
FCF
|
|||
| — | — | — | — | 214 | 755 | 654 | 602 | 468 | 489 |
Working Cap'
|
|||
| — | — | — | — | — | 3 | 4 | — | 6 | 53 |
Total Debt
|
|||
| — | — | — | — | (216) | (762) | (657) | (611) | (496) | (476) |
Net Debt
|
|||
| — | — | — | — | 215 | 746 | 655 | 605 | 464 | 306 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (37.57%) | (17.41%) | (14.39%) | (11.72%) | (97.74%) | (36.04%) |
ROA
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | (8.67%) | (18.07%) | (14.87%) | (12.03%) | (106.27%) | (53.18%) |
ROE
|
|||
Nuvation Bio Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| URGN Urogen Pharma | $2.0B | 0.0× | Compare |
| VCEL Vericel Corporation | $2.0B | 82.6× | Compare |
| MESO Mesoblast Limited | $2.0B | 0.0× | Compare |
| AGIO Agios Pharmaceuticals, Inc. | $2.0B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BHVN Biohaven Ltd. | $2.0B | 0.0× | Compare |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.0B | 0.0× | Compare |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.0B | 0.0× | Compare |
| SRPT Sarepta Therapeutics, Inc. | $2.0B | 0.0× | Compare |
Nuvation Bio Inc. (NUVB) key facts
- Nuvation Bio Inc. (NUVB) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024.
- As of September 25, 2026, NUVB traded at $5.74, a market capitalization of $2.0 billion.
- Return on equity was −53.2% and debt-to-equity 0.98.
Nuvation Bio Inc. (NUVB) Latest News
17 Sep
Nuvation Bio secures FDA approval for supplemental new drug application updating duration of response data for IBTROZI in TKI-naïve advanced ROS1-positive non-small cell lung cancer. FDA approval of updated IBTROZI labeling strengthens Nuvation Bio's competitive position and commercialization prospects in ROS1-positive NSCLC.
16 Sep
Nuvation Bio reports IBTROZI efficacy across ROS1 lung cancer subgroups. Positive efficacy results in key lung cancer subgroups boost prospects for regulatory approval and revenue growth.
15 Sep
Nuvation Bio announced new analyses at the 2026 World Conference on Lung Cancer showing IBTROZI (taletrectinib) delivers durable, consistent efficacy across key patient subgroups in advanced ROS1+ NSCLC. Positive efficacy data on taletrectinib strengthens Nuvation Bio's position in ROS1+ NSCLC and supports future market performance.
20 Aug
JPMorgan projects 100% upside for Nuvation Bio Inc. (NUVB) stock, citing its overlooked cancer drug assets as a key opportunity. JPMorgan's 100% upside call on NUVB can drive major investor inflows and sharply lift near-term stock performance.
Nuvation Bio Inc. (NUVB) received FDA Fast Track Designation for Safusidenib to treat IDH1-mutant glioma. FDA Fast Track accelerates Safusidenib development and review, materially strengthening NUVB pipeline prospects and valuation.
13 Aug
Nuvation Bio Inc. (NUVB) held its Q2 2026 earnings call covering financial results, operational updates, and forward guidance. Earnings call supplies performance metrics and strategy details that can shift near-term investor sentiment.
8 Aug
Nuvation Bio reported Q2 financial results and provided updates on its oncology pipeline, clinical trials, and cash position during the earnings call. Quarterly earnings call supplies financial and pipeline updates that moderately influence near-term investor sentiment and operations.
6 Aug
Nuvation Bio Inc. held its Q2 2026 earnings call, covering financial results, operational updates, and forward-looking statements for the biotech company. Quarterly earnings calls deliver financial metrics and guidance that can moderately shift near-term investor views without guaranteeing major strategic shifts.
Nuvation Bio Inc. reported second quarter 2026 financial results and provided a business update. Quarterly financial results deliver performance metrics that influence investor sentiment and short-term valuation.
4 Aug
Nuvation Bio (NUVB) positions IBTROZI’s TRUST data as a competitive edge in targeted lung cancer therapy. TRUST data on core lung cancer therapy can materially shift Nuvation Bio’s clinical positioning and investor outlook.
Nuvation Bio will present new subgroup analyses of pivotal trial data for IBTROZI (taletrectinib) in advanced ROS1-positive non-small cell lung cancer at the WCLC and ESMO annual congresses. Conference presentations of subgroup analyses provide incremental visibility for taletrectinib but do not shift core development or regulatory milestones.
22 Jul
RBC analysts state Nuvation Bio's safusidenib clinical program and Ibtrozi opportunity create a favorable setup. Positive RBC commentary on clinical programs and product opportunities can boost investor sentiment and NUVB stock performance.
20 Jul
Nuvation Bio Inc. (NUVB) stock surges as RBC Capital Markets assigns a $3 billion opportunity to the company's brain cancer drug. RBC's $3B valuation of Nuvation Bio's brain cancer drug signals major commercial potential that can reshape investor outlook and company trajectory.
Nuvation Bio reports positive updated Phase 2 data for safusidenib and expands its clinical program with two new studies targeting IDH1-mutant glioma. Positive Phase 2 data plus program expansion strengthen safusidenib development prospects in glioma.
6 Jul
Nuvation Bio Inc. announced full exercise of the greenshoe option in its $287.5 million convertible senior notes offering. The $287.5 million capital raise improves Nuvation Bio's cash position and extends operational runway.
2 Jul
Nuvation Bio Inc. advances Taletrectinib expansion to strengthen its global oncology presence and competitive positioning. Taletrectinib footprint expansion marks a major strategic oncology move that can shift company trajectory and investor views.
1 Jul
Nuvation Bio Inc. executive with medical background outlines mergers and acquisitions strategy. M&A playbook disclosure signals potential strategic transactions ahead for Nuvation Bio.
29 Jun
Nuvation Bio announces validation of its Marketing Authorisation Application for Taletrectinib to treat advanced ROS1-positive non-small cell lung cancer in the United Kingdom. UK validation of taletrectinib application marks key regulatory progress that can accelerate approval and commercial launch for Nuvation Bio's lead asset.
26 Jun
Nuvation Bio Inc. prices $250 million convertible senior notes offering. Convertible bond issuance supplies Nuvation Bio with substantial capital while creating potential future share dilution.
25 Jun
Nuvation Bio Inc. priced an upsized $250.0 million offering of convertible senior notes. The $250 million convertible notes raise provides substantial capital that directly supports ongoing operations and pipeline development.
Nuvation Bio Inc. proposes to offer convertible senior notes. Convertible notes offering supplies funding for Nuvation Bio development activities while carrying potential future dilution.
17 Jun
Veteran Pharma VC Insider purchased 25,000 Nuvation Bio Inc. shares as its new drug gains momentum. Insider share purchase amid drug development progress indicates potential positive market sentiment shift for Nuvation Bio.
16 Jun
Acquisition of Nuvalent alters competitive positioning for Nuvation Bio (NUVB) in precision oncology, potentially affecting market dynamics and strategic outlook for the company. Nuvalent acquisition shifts competitive landscape and market positioning for Nuvation Bio.
27 May
Nuvation Bio will present new quality-of-life data for IBTROZI (taletrectinib) in ROS1-positive non-small cell lung cancer patients at the ASCO 2026 Annual Meeting. Announcement of upcoming taletrectinib data presentation at ASCO may moderately lift Nuvation Bio's pipeline visibility and near-term sentiment.
18 May
Nuvation Bio advances IBTROZI development through expanded Thermo Fisher collaboration and new FDA regulatory steps targeting oncology applications. Thermo Fisher partnership plus FDA progress directly accelerates IBTROZI regulatory path and commercial readiness.
13 May
Nuvation Bio Inc. (NUVB) announces collaboration with Thermo Fisher Scientific for U.S.-based manufacturing of IBTROZI®, its treatment for ROS1-positive non-small cell lung cancer. Strategic U.S. manufacturing partnership with Thermo Fisher bolsters IBTROZI® supply chain and commercialization for ROS1-positive NSCLC, significantly aiding NUVB's market trajectory.
8 May
Nuvation Bio Inc. beat analyst profit forecasts, prompting analysts to issue new estimates. Beating profit forecasts and triggering new analyst estimates signals strong financial momentum likely to enhance investor sentiment and stock trajectory.
6 May
Nuvation Bio Inc. (NUVB) announced FDA acceptance of its supplemental New Drug Application for IBTROZI (taletrectinib), incorporating updated duration of response data from the TRUST-I and TRUST-II trials in patients with advanced ROS1-positive non-small cell lung cancer. FDA acceptance of sNDA with updated DoR data strengthens IBTROZI's label potential in ROS1+ NSCLC, boosting Nuvation Bio's oncology pipeline and investor sentiment.
4 May
Nuvation Bio Inc. released Q1 2026 earnings call summary detailing financial results, pipeline updates, and forward guidance. Q1 2026 earnings call summary discloses key financials, clinical progress, and strategic outlook, poised to drive substantial shifts in market performance and investor confidence.
Nuvation Bio Inc. (NUVB) reported Q1 2024 results with $134.5 million cash reserves providing runway into 2026, $20.5 million net loss, advanced taletrectinib ROS1 inhibitor with positive phase 2 TRUST-II data and planned registrational trials, continued NUV-868 BET inhibitor development, and terminated magrolimab license. Pipeline advancements and cash runway sustain operations amid ongoing losses, exerting moderate influence on financials and investor sentiment.